Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.
Evidence based guidelines are presented on the selection and use of therapeutic products to treat haemophilia. These guidelines offer advice based on the best published scientific and medical information. They will be reviewed regularly by UKHCDO Advisory Committee. Included are details of therapeutic products available in the UK to treat patients with haemophilia and other bleeding disorders and the background information on which the recommendations are based are presented.
D025861:Blood Coagulation Disorders, Inherited / Q000188:drug therapy*; D001779:Blood Coagulation Factors / Q000592:standards / Q000627:therapeutic use*; D004356:Drug Storage / Q000379:methods; D019317:Evidence-Based Medicine; D005164:Factor IX / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy; D002836:Hemophilia B / Q000188:drug therapy; D006801:Humans; D008297:Male; D018579:Patient Selection; D011994:Recombinant Proteins / Q000627:therapeutic use; D006113:United Kingdom; D014842:von Willebrand Diseases / Q000188:drug therapy
D001779:Blood Coagulation Factors; D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX